Pfizer gets early FTC clearance for Metsera acquisition

Go back to Pfizer gets early FTC clearance for Metsera acquisition

Novo Nordisk earnings preview: Barclays and BofA weigh in

November 4, 2025 4:00 PM UTC

Barclays and Bank of America both expect Novo Nordisk's (NYSE: NVO) third-quarter results on November 5 to come broadly in line with expectations but warn the drugmaker could lower the upper end of its 2025 guidance as prescription trends soften.

Barclays analyst Yihan Li said the bank now models +10.9% FY25 topline CER growth (generally in-line with guidance... More

Pfizer earnings preview: Leerink trims estimates

November 3, 2025 4:00 PM UTC

Pfizer (NYSE: PFE) is set to report third-quarter results on Nov. 4, with analysts at Leerink Partners lowering earnings forecasts ahead of the release.

Leerink reduced its third-quarter earnings-per-share estimate by $0.10, or 13%, to $0.70, and full-year 2025 EPS by 3% to $3.04, within company guidance ($2.90$3.10).

The firm said it cut its 2025 Paxlovid... More